For Manuscript Submission, Check or Review Login please go to Submission Websites List.
For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.
Assessment of Respiratory Physiology of C57BL/6 Mice following Bleomycin Administration Using Barometric PlethysmographyMilton P.L.a · Dickinson H.b · Jenkin G.b · Lim R.b
aMonash Immunology and Stem Cell Laboratories, Monash University and bThe Ritchie Centre, Monash Institute of Medical Research, Clayton, Vic., Australia Corresponding Author
Dr. Rebecca Lim, PhD
The Ritchie Centre
Monash Institute of Medical Research
27-31 Wright Street, Clayton, VIC 3168 (Australia)
Tel. +61 3 9594 7410, E-Mail firstname.lastname@example.org
Background: Assessment of deterioration of lung function in animal models of respiratory disease traditionally relies upon quantitating biochemical markers. Plethysmography is a technique for measuring lung function that includes invasive and non-invasive methodologies. Objectives: This study used whole-body barometric plethysmography to characterize change(s) in respiratory physiology of C57BL/6 mice following bleomycin administration. Methods: Cohorts of animals were culled at 3, 7, 14 and 28 days to semi-quantitatively score the lung for fibrosis, and quantitate levels of hydroxyproline in the lung. We have described in detail the response of C57BL/6 mice to bleomycin. Results: Bleomycin-treated mice had reduced minute volume (p < 0.05) and an increased total breathing cycle time (p < 0.0001), which consisted of a shortened inspiration time (p < 0.01) and an extended expiration time (p < 0.0001). Conclusions: We have demonstrated that plethysmography can be a primary indicator of the development of respiratory disease in the mouse and would thus be suitable in assessing potential therapies since any truly effective treatment should elicit restoration of respiratory parameters in addition to improving traditional biochemical and histological indices of lung function.
© 2011 S. Karger AG, Basel
Quantitative assessment of pulmonary function in animal models of respiratory disease is of scientific importance and clinical relevance. Plethysmography is also used clinically for investigating respiratory physiology of unrestrained human subjects performing their daily activities, and can be modified to take into account position changes . Invasive plethysmography has been used in both ventilated and spontaneously breathing, anaesthetized animals via orotracheal or percutaneous tracheal intubation . Measurements taken from anaesthetized, paralyzed and tracheotomized mice are precise and specific, but are obtained whilst the animal is in an unnatural state . By contrast, unrestrained whole-body plethysmography is a non-invasive procedure whereby re-spiratory function is precisely measured in conscious, uninstrumented subjects . This non-invasive method of plethysmography is a valuable technique for assessing respiratory physiology as respiratory function of individual animals can be assessed on multiple occasions in longitudinal studies, free of anaesthetic and invasive manipulations [4,5].
The ability of the chemotherapeutic agent bleomycin to induce pulmonary fibrosis has been utilized by researchers in experimental animal models of the human disease pulmonary fibrosis. The bleomycin model is easy to establish, robust, reproducible and versatile  and was originally developed in dogs , then adapted to mice [8,9], hamsters , rats [11,12] and rabbits [13,14]. To induce pulmonary fibrosis, bleomycin may be administered by various routes, including intratracheal , intranasal , intraperitoneal  and osmotic mini-pump  administration. The type, severity and pattern of parenchymal lesions arising following bleomycin administration are route and dose dependent . The potential to induce a variety of lesions offers the advantage of studying pulmonary fibrosis with heterogeneous topography of the lung, a feature similar to some forms of idiopathic interstitial pneumonitis .
Investigators often overlook evaluating pulmonary physiological function in animal models of respiratory diseases that aim to assess potential therapies and treatment regimens as biochemical analyses of lung tissue are primarily used as indicators of disease suppression and/or regression. We aim to use whole-body barometric plethysmography to describe changes in respiratory physiology during the course of disease development and progression in C57BL/6 mice following bleomycin-induced pulmonary fibrosis. This study may provide an accessible and useful analytical technique for evaluating respiratory physiology, which would have a wide application in animal models of respiratory diseases and would be especially useful for investigating the efficacy of new drugs, treatment strategies and regimens, which are currently being developed as therapies for human pulmonary fibrosis.
All experimental procedures were approved by the School of Biomedical Sciences Animal Ethics Committee at Monash University and conducted in accordance with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes (2006).
The adult female C57BL/6 mice used in this study were obtained from the Animal Resources Centre, Perth, W.A., Australia. Upon commencement of the study, animals were 19.0 ± 0.08 g in weight and aged 8-12 weeks. C57BL/6 mice were housed in a specific pathogen-free temperature- and humidity-controlled room (21.0 ± 1.0°C and 50.0 ± 10.0%, respectively) with a 12-hour light-dark cycle. Mice had access to water and food ad libitum.
The plethysmograph used to measure pulmonary function in vivo was modified from that previously described for assessing pulmonary function in guinea pigs . The plethysmograph (fig. 1) consisted of a single cylindrical Perspex chamber (150 × 50 mm) with a temperature and relative humidity probe (model HM34; serial No. 413576; Vaisala, Finland) inserted at one end. A volumetric pressure transducer (model PT5A; serial No. L302P4; Grass Instrument Co., Quincy, Mass., USA) and a 1-ml calibration syringe were inserted at the other end of the chamber. The pressure transducer measured the change in pressure caused by the tidal movement of gas within the chamber. This signal was then amplified (Octal Bridge Amp model ML228; Powerlab 8/30 model ML870; AD Instruments) and recorded with a data recording program (Chart 5 for Windows, version 5.1) using a standard desktop PC. Animal core temperatures were measured with a rectal thermometer (Livingstone) prior to recording. The pulmonary function of each mouse was recorded for a maximum of 45 s and, if during this time the animal was not stationary and calm, the chamber ends were removed for re-equilibration of the chamber with the external environment and, after several minutes, recordings were taken again and the original recording discarded.
Waveform analysis (Chart 5 for Windows, version 5.1) was used to analyse the respiratory trace obtained from each animal. This consisted of the change in pressure caused by the tidal movement of gas within the chamber (PT) and a pressure deflection that related to a volume of air injected for calibration (Vk). The respiratory parameters of breathing frequency (f, breaths/min), total breathing cycle time (Ttot, s), inspiration time (Ti, s) and expiration time (Te, s) were derived directly from the respiratory trace and were taken from regions of the trace void of sniffing or movement waveforms. To calculate tidal volume (VT, ml), the PT value obtained from the respiratory trace was inputted into the equation of Drorbaugh and Fenn  as below.
VT = (PT/Pk) × (Vk) × ((Tcore (PB - PC))/(Tcore (PB - PC) - TC (PB - Pcore))),
where VT = tidal volume; Pk = pressure deflection due to each injection of 1 ml; Tcore = core temperature of each animal; PC = water vapour pressure at chamber temperature (water vapour pressure at chamber temperature × relative humidity in chamber); TC = temperature in animal chamber; Pcore = pressure at body temperature (water vapour pressure at body temperature × 1.0); PT = pressure deflection due to each tidal volume; Vk = volume injected for calibration; PB = barometric pressure.
Once tidal volume had been determined, minute volume (VE, ml/min; VT × f), inspiratory duty cycle (Ti/Ttot, %), inspiratory flow rate (VT/Ti, ml/s) and the ratio of inspiration time to expiration time (Ti/Te ratio) were also calculated.
Body weight and basal lung function of the C57BL/6 mice were recorded prior to administering bleomycin or vehicle (saline). These parameters were recorded again at 3, 7, 14, 21 and 28 days following administrations. After the recordings on days 3, 7, 14 and 28, a cohort of animals (n = 15 at days 3, 7, 14; n = 5 at day 28) were culled from the untreated control and bleomycin treatment groups for tissue collection and analyses as described below.
Under light isoflurane (Attane™, Minrad, N.S.W., Australia) anesthesia, a bolus intranasal administration of bleomycin (Sigma, USA) was administered to C57BL/6 mice to induce pulmonary fibrosis. A range of doses (mg/mouse) were trialled (0.15, 0.2, 0.25, 0.275. 0.3, 0.35 and 0.4), with 0.25 mg/mouse (n = 50) being the selected dose as pulmonary fibrosis was induced consistently in all animals with no mortality (data not shown). Control mice received saline alone by the same procedure (n = 50).
Animals were culled by an intraperitoneal injection of 150 mg/kg Lethobarb (Virbac, Australia). The right lung was ligated at the right mainstem bronchus, excised and weighed to determine wet lung weight. The right lung was then processed for the hydroxyproline assay as described below. Upon excising the right lung, the trachea was then exposed, cannulated and the left lung was instilled with 10% phosphate-buffered formalin at 25 cm H2O pressure. The left lung was then excised and immersed in the same fixative for 48 h and processed for paraffin embedding. Serial sections, at 5 µm in thickness, were then taken and stained with Masson's trichrome or haematoxylin and eosin.
A numerical fibrotic score (Ashcroft scale ) was obtained as follows; the severity of the fibrotic changes was determined as the mean score and standard error of the mean (SEM) from more than 25 microscopic fields at 200× magnification for each lung section, and each field was assessed individually for severity and allotted a score from 0 (normal) to 8 (total fibrosis). All lung sections were evaluated in a blinded fashion by two independent observers.
Morphological changes in lung sections were graded semi-quantitatively as previously published [22,23]. Three histological sections per lung were graded using the following criteria: 0 = normal lung; 1= minimal areas of inflammation, epithelial hyperplasia and fibrosis, usually limited to subpleural foci in just 1 or 2 sections; 2 = more frequent lesions; 3 = all 3 sections exhibit lung lesions which are not limited to subpleural foci; 4 = extensive lesions in at least 2 of 3 sections, and 5 = the majority of each of 3 lung sections affected by inflammation and fibrosis.
The excised right lung was lyophilized to dry weight to determine the hydroxyproline content as described previously . The hydroxyproline concentrations were expressed as a proportion of animal body weight (micrograms hydroxyproline per lung lobe).
Results are expressed as means ± SEM. Lung function parameters, body weight and body temperature data were evaluated for statistical significance using the repeated-measures general linear model analysis in SPSS (version 13.0). Parameters that were statistically significant were then analysed by multiple analysis of variance (ANOVA) with a Bonferroni post hoc analysis of time, with treatment as the fixed factor. A two-way ANOVA was used to determine differences in wet lung weight data and histological scores. Statistical significance was tested to the 5% level (p < 0.05).
Bleomycin treatment had a similar effect on both core body temperature and weight (fig. 2). The overall differences observed between vehicle control and bleomycin-treated C57BL/6 mice over the 28-day study period were not statistically significant for either body temperature (fig. 2a, p = 0.06) or weight (fig. 2b, p = 0.09). However, when days 21 and 28 were excluded from the statistical analyses, there was an overall significant difference observed between vehicle control and bleomycin-treated C57BL/6 mice for body temperature (p < 0.0001) and weight (p < 0.0001). Within 7 days of bleomycin treatment, C57BL/6 mice had experienced a loss in body temperature and weight from an initial 37.7 ± 0.06°C and 19.07 ± 0.8 g to 34.8 ± 0.30°C and 15.5 ± 0.4 g, respectively, compared to vehicle control mice which maintained a consistent body temperature (37.6 ± 0.04°C) and weight (19.35 ± 0.08 g) for the duration of the 28-day study period. From days 7 to 28, bleomycin-treated C57BL/6 mice regained body temperature and weight to within basal levels, reaching values of 36.94 ± 0.32°C and 19.48 ± 0.8 g, respectively, by day 28 (fig. 2).
Effect of Bleomycin on Tidal Volume, Respiratory Rate, and Minute Ventilation
The overall differences observed in tidal volume between untreated control and bleomycin-treated mice over the study period were not statistically significant. Three days after bleomycin administration, tidal volume of bleomycin-treated mice was reduced but returned to within basal levels by day 7 (fig. 3a). When tidal volume was calculated relative to body weight, it was maximal at day 7 (5.03 ± 0.19 ml/kg) but returned to within basal levels by day 14 (fig. 3b).
There was an overall significant difference observed between untreated control and bleomycin-treated C57BL/6 mice for breathing frequency (p < 0.0001), with days 3, 7 and 14 significantly different to days 0, 21 and 28 (p < 0.0001; fig. 3c). Respiratory rate of bleomycin-treated C57BL/6 mice decreased by 40.8% from an initial 348.21 ± 3.8 breaths/min to 206.34 ± 5.9 breaths/min by day 3. This rate was maintained until day 7, at which point, breathing frequency began to increase to within basal levels by day 21 (335.11 ± 36.5 breaths/min; fig. 3c). When expressed relative to body weight, significant differences were only seen on days 3 and 7 (p < 0.0001; fig. 3d).
Minute volume was also significantly different between vehicle control and bleomycin-treated C57BL/6 mice (p < 0.05), and showed a similar trend from that of breathing frequency, whereby minute volume on days 3 and 7 was significantly different to that on days 0, 14, 21 and 28 (p < 0.0001; fig. 3e). Bleomycin-treated C57BL/6 mice had experienced a 49.2% reduction in minute volume by day 3 following treatment, which gradually increased to within basal levels by day 21 (fig. 3e). When minute volume was calculated relative to body weight, the overall differences observed between vehicle control and bleomycin-treated mice were not significant (fig. 3f).
Following bleomycin treatment, tidal volume and minute volume were significantly positively correlated (r = 0.48; p < 0.0001). Minute volume and breathing frequency were also significantly positively correlated (r = 0.84; p < 0.0001) while tidal volume and breathing frequency were negatively correlated (r = -0.05; p > 0.05).
The overall differences observed for total breathing cycle time between vehicle control and bleomycin-treated C57BL/6 mice were statistically significant (p < 0.0001), with days 3 and 7 significantly different to days 0, 14, 21 and 28 (p < 0.0001; fig. 4a). By day 3 following bleomycin administration, treated C57BL/6 mice had a significantly longer total breathing cycle time (0.30 ± 0.01 s; p < 0.0001; fig. 4a) compared to the cycle time at the time of treatment (0.17 ± 0.002 s). Breathing cycle time of bleomycin-treated C57BL/6 mice remained extended until day 7, at which point it began to shorten and was not significantly different to basal levels by day 21 (0.18 ± 0.02 s).
Total breathing cycle time was further analysed with respect to the duration of inspiration and expiration. For inspiration time, there was an overall significant difference observed between vehicle control and bleomycin-treated C57BL/6 mice (p < 0.01), with all time points of analyses significantly different to basal readings (p < 0.0001; fig. 4b). Similarly, there was an overall statistically significant difference observed between vehicle control and bleomycin-treated C57BL/6 mice for expiration time (p < 0.0001), with days 3 and 7 significantly different to days 0, 14, 21 and 28 (p < 0.0001; fig. 4c). Like total breathing cycle time, by day 3 following bleomycin administration, inspiration and expiration times were both significantly different to basal levels (p < 0.0001). Inspiration time was significantly shorter and expira- tion time significantly longer, with durations of 0.066 ± 0.001 s and 0.24 ± 0.01 s at day 3 compared to basal levels of 0.081 ± 0.001 s and 0.092 ± 0.001 s, respectively (fig. 4b, c). For the remainder of the study period, from day 3 to day 28, inspiration time continued to become increasingly shorter for bleomycin-treated C57BL/6 mice compared to vehicle controls. Expiration time remained extended between 3 and 7 days following treatment at which point, like total breathing cycle time, it began to shorten towards basal readings (fig. 4b, c).
Over the study period, the ratio of inspiration time to expiration time was significantly different between vehicle control and bleomycin-treated mice (p < 0.0001), with all time points of analyses significantly different to basal readings (p < 0.0001; fig. 4d). Vehicle control animals had a symmetrical breathing cycle, Ti/Te ratio, with inspiration and expiration times of essentially equal duration, indicated by a ratio close to 1.0 (0.86 ± 0.01). Prior to treatment, mice receiving bleomycin also had a symmetrical breathing trace (0.88 ± 0.01); however, by day 3, the Ti/Te ratio was significantly smaller (0.29 ± 0.01; p < 0.0001). The Ti/Te ratio for bleomycin-treated C57BL/6 mice from day 3 and for the remainder of the study period remained below 0.5, indicating an asymmetric breathing cycle (fig. 4d).
Following bleomycin treatment, inspiration and expiration times were significantly positively correlated with total breathing cycle time, with r values of 0.42 (p < 0.0001) and 0.97 (p < 0.0001), respectively.
The overall differences observed between vehicle control and bleomycin-treated mice for inspiratory flow rate were significant (p < 0.05), with days 7, 14, 21 and 28, significantly different to basal readings and those recorded at day 3 following treatment (p < 0.0001; fig. 5a). Mice treated with bleomycin experienced a gradual increase in inspiratory flow rate from day 3 (1.04 ± 0.02 ml/s), and for the remainder of the study period, until a maximum of 1.48 ± 0.29 ml/s was reached by day 28 (fig. 5a). Mice in the vehicle control group had a stable inspiratory flow rate of 0.99 ± 0.01 ml/s for the duration of the study period.
Similarly, there was an overall significant difference observed between vehicle control and bleomycin-treated mice for inspiratory duty cycle (p < 0.0001), with all time points of analyses significantly different to basal readings (p < 0.0001; fig. 5b). Bleomycin-treated C57BL/6 mice had experienced a 51.8% reduction in inspiratory duty cycle by day 3 following treatment. Between days 7 and 21, inspiratory duty cycle had partially recovered (30.11 ± 2.73%) but not to within basal levels (46.98 ± 0.27%; fig. 5b). This is compared to vehicle control mice that had a stable inspiratory duty cycle of 46.34 ± 0.32% for the duration of the study period.
Following bleomycin treatment, inspiratory flow rate and inspiratory duty cycle were significantly negatively correlated with total breathing cycle time, with r = -0.30 (p < 0.01) and r = -0.70 (p < 0.0001), respectively.
An overall significant difference was observed in wet lung weights between vehicle control and bleomycin-treated mice (p < 0.0001; fig. 6a). At each time point of analysis, mice in the bleomycin-treated group had significantly heavier lungs than mice in the vehicle control group, with wet lung weights of 0.115 ± 0.007 g (p < 0.001), 0.145 ± 0.006 g (p < 0.001), 0.133 ± 0.011 g (p < 0.001) and 0.153 ± 0.013 g (p < 0.001), at days 3, 7, 14 and 28, respectively. Mice in the vehicle control group had a wet lung wet of approximately 0.084 ± 0.004 g for the duration of the study period (fig. 6a). The wet lung weight relative to body weight values had a similar trend to the wet lung weights per se, with an overall significant difference observed between vehicle control and bleomycin-treated mice (p < 0.0001), and also between vehicle control and bleomycin-treated mice at each time point studied (p < 0.01; fig. 6b).
Lungs of vehicle control mice had normal alveolar architecture with no evidence of extracellular matrix ac-cumulation or inflammatory cell infiltrate. Bleomycin-treated mice had patchy lesions in the pulmonary architecture, which were characterized by areas of dense inflammatory cell infiltrate that obliterated the alveoli and which were interspersed with areas of less severe lesions, where alveolar walls were thickened and fibrous masses and bands had accumulated (fig. 7). There was an overall significant difference observed between untreated control and bleomycin-treated mice for the severity of parenchymal lesions by Ashcroft scoring (p < 0.0001) and the morphological index (p < 0.0001). At each time point of analysis, mice in the bleomycin-treated group had significantly more severe and widespread distribution of lesions than those in the vehicle control group (p < 0.001), with Ashcroft scores of 4.48 ± 0.34, 5.62 ± 0.82 and 5.22 ± 0.20 at days 3, 14 and 28, respectively (fig. 7, 8a). The most severe parenchymal lesions were of a subpleural, perivascular, peribronchial and bronchiolocentric distribution (fig. 8b). At day 14, lungs of bleomycin-treated mice had the most severe and widespread distribution of lesions.
There was an overall significant difference observed between vehicle control and bleomycin-treated mice for hydroxyproline content in the lung (p < 0.0001; fig. 9). At day 7, hydroxyproline concentration in the lung of bleomycin-treated mice was significantly greater than that in vehicle control mice (14.77 ± 1.21 and 9.44 ± 0.29 µg/g, respectively). Similarly, bleomycin-treated C57BL/6 mice had a significantly greater hydroxyproline concentration in the lung than vehicle control mice at day 28 following administration (9.11 ± 1.19 and 4.42 ± 0.27 µg/g, respectively). Interestingly, we noted that hydroxyproline content was lower 28 days following vehicle instillation compared to 3, 7 and 14 days following instillation. This may indicate some extent of injury brought on by saline instillation.
Using a non-invasive method of unrestrained whole-body barometric plethysmography, we described in detail the changes in respiratory physiology and breathing cycle parameters of C57BL/6 mice following bleomycin induction of pulmonary fibrosis. Recently, Vanoirbeek et al.  published their findings on invasive and non-invasive methods of measuring pulmonary functions in obstructive and restrictive diseases, where lung func tion was analysed at a single time point following vari ous asthmatic, emphysematic and bleomycin challenges. Unique to our study, we show the changes to respiratory physiology in bleomycin injured mice over time by employing exhaustive techniques in unrestrained whole-body plethysmography and histological analyses.
Following bleomycin administration, the pulmonary function of C57BL/6 mice was adversely affected, whereby significant changes in volumetric and breathing cycle parameters were observed. These changes were a likely consequence of the severe morphological alterations occurring in the lung following bleomycin treatment, which manifested as a heterogeneous distribution of dense inflammatory cell infiltrate and accumulations of fibrous masses and bands in the lung parenchyma, coupled with thickening of the alveolar walls, all of which are observations consistent with previous reports [26,27,28]. Likewise, as with previous reports, bleomycin-treated C57BL/6 mice developed pulmonary oedema, deduced from the significant increase in wet lung weights following bleomycin treatment, compared to vehicle control mice [29,30]. Furthermore, albeit not a significant difference, the observed reduction in body weight of bleomycin-treated C57BL/6 mice was likely to be the outcome of the brisk inflammatory response occurring in the lung as previously reported [29,31,32,33,34,35].
Collectively, the morphological changes occurring in the lungs of bleomycin-treated C57BL/6 mice were likely to have reduced the surface area available for gas exchange, a defining characteristic of the bleomycin model [8,36]. As a result, bleomycin-treated C57BL/6 mice experienced a loss in respiratory function, which was characterized by a decrease in tidal volume. In order to minimize the work of breathing, the observed reduction in tidal volume was accompanied by a decrease in breathing frequency, a normal physiological response . C57BL/6 mice had a rapid, shallow breathing pattern, which was likely to have been due to lung vagal afferents, which are known to cause this breathing pattern following bleomycin induction of pulmonary fibrosis in animals [38,39].
In addition to causing a loss in respiratory function, the significant morphological changes occurring in the lung following bleomycin treatment develop in association with extracellular matrix remodelling, which collectively impact on the oscillatory mechanics of the lung [8,36,40]. As a consequence of the parenchymal lesions and extracellular matrix remodelling, lungs of bleomycin-treated animals in models of pulmonary fibrosis have reduced compliance , increased elastic recoil, which is the inverse of compliance , and an increase in lung resistance [40,43]. Given that the observed morphological changes in lungs of C57BL/6 mice are consistent with previous reports, the properties of altered compliance, elastic recoil and resistance are likely to apply to our model. This, in turn, is likely to have resulted in the significant changes in the physiological cyclic parameters observed.
The total breathing cycle time of bleomycin-treated C57BL/6 mice was significantly increased following bleomycin administration. This change in the length of the breathing cycle was due in part to the development of an asymmetric breathing pattern, characterized by a proportionately longer expiration time than inspiration time. As a consequence of the inferred reduced compliance in the lungs of bleomycin-treated C57BL/6 mice, and as expiration is normally a passive process , inspiration was likely to have been more difficult and therefore required greater effort. There was thus a significant increase in inspiratory flow rate, the active component of the breathing cycle, which was accompanied by a significant reduction in inspiratory duty cycle, the timing component of the breathing cycle. Thus, the rate of airflow during inspiration increased with a consequent reduction in the duration and contribution of inspiration to the breathing cycle. Furthermore, the significant increase observed in expiration time following bleomycin treatment may be attributed to the greater tissue resistance in the lungs of bleomycin-treated C57BL/6 mice. These observations were in contrast to those observed in vehicle control C57BL/6 mice, which maintained a symmetric breathing pattern for the duration of the study period, whereby inspiration and expiration were of essentially equal duration, in addition to maintaining a steady inspiratory flow rate and duty cycle.
Measuring pulmonary function in animal models of respiratory disease is of scientific importance and clinical relevance. Several studies have reported the use of plethysmography following bleomycin treatment [40,43,44,45,46,47,48,49,50]. Of the reported studies, the majority utilized invasive plethysmography on anaesthetized mice supported by mechanical ventilation at a rate of 150 breaths/min, a tidal volume of 7.5-8 ml/kg and a positive end-expiratory pressure of approximately 3-4 cm H2O [40,43,44,50]. Invasive plethysmography is useful in assessing respiratory mechanics, such as static compliance, lung resistance and elasticity; however, these procedures are tedious, require surgery, and measurements are taken whilst the animal is in a manipulated and unnatural state. Furthermore, the invasive nature of the procedure does not permit longitudinal studies in individual animals. Micro-computed tomography has been utilized several studies to assess lung compliance of bleomycin-treated animals; however, this procedure is tedious and expensive [46,47,48].
Another technology widely available for measuring respiratory parameters is the forced oscillation technique. This allows for the detection of subtle changes in comparison to whole-body plethysmography; however, the forced oscillation technique requires the termination of animals, unlike whole-body plethysmography, which allows repeat measurements on the same unrestrained unanaesthetized animal. It is also important to note that while whole-body plethysmography appeared to yield expected and significant changes in the bleomycin injury model used in this study, its application across to allergic airway disease models may be limited. It has been previously suggested that whole-body plethysmography is more reliable for detecting changes to breathing patterns than it is for detecting changes to lung mechanics [54,55]. While whole-body plethysmography and enhanced pause (Penh) have their merits in helping our understanding of respiratory physiology in disease processes, we caution against their use as standalone methods for lung function analysis.
Reported studies that included whole-body barometric plethysmography following bleomycin treatment, only briefly examined breathing frequency, tidal volume or Penh, which is a measure of airway function and bronchoconstriction and is calculated from the pressure, measured by the plethysmograph as a function of time [45,49,51]. There is debate regarding the validity of Penh as an indicator of bronchoconstriction and its representation of airway function [51,52,53]. Despite the limited assessment of respiratory parameters in the reported studies which utilized plethysmography following bleomycin treatment, whole-body barometric plethysmography can provide a substantial quantity of lung function data that quantify volumetric and cyclic breathing parameters as demonstrated by this study on C57BL/6 mice, especially given that multiple recordings over time can be performed on any individual animal with no residual effects of anaesthesia or surgery.
Analyses of lung function in animal studies of respiratory disease are frequently overlooked as investigators primarily focus on utilizing the outcome of biochemical analyses of lung tissue as indicators of disease suppression and/or regression [30,33,56,57,58,59,60,61,62]. The results from this study on C57BL/6 mice illustrate that the inclusion of whole-body barometric plethysmography would benefit any study utilizing the bleomycin animal model of pulmonary fibrosis, particularly if potential therapies are being investigated, as this technique is appropriate for the longitudinal assessment of disease progression, regression and restoration of respiratory function. In the assessment of the effectiveness of potential therapeutic agents, respiratory physiology and evaluation of improvement in respiratory parameters are fundamental to the identification of improved lung mechanics.
In summary, this study characterized the kinetics of respiratory physiology and breathing cycle parameters of C57BL/6 mice following bleomycin administration in an animal model of pulmonary fibrosis. Given the considerable impact of pulmonary fibrosis on respiratory function and mechanics, the results of this study have demonstrated that whole-body barometric plethysmography would be a useful addition to animal studies investigating potential therapies, and should form one of the primary indicators of disease progression and regression as any truly effective treatment would elicit restoration of respiratory parameters in addition to improvement of traditional biochemical and histological indices of lung function.
Appreciation is extended to Prof. John Wilson (Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital) for providing advice on the manuscript.
This research was partially funded by an NHMRC Project Grant No. 491145 and the Victorian Government's Operational Infrastructure Support Program. P.L.M. was in receipt of an Australian Stem Cell Centre Premier Scholarship during her PhD studies. H.D. is supported by an ARC Australian Post-Doctoral Research Fellowship.
Dr. Rebecca Lim, PhD
The Ritchie Centre
Monash Institute of Medical Research
27-31 Wright Street, Clayton, VIC 3168 (Australia)
Tel. +61 3 9594 7410, E-Mail email@example.com
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.